Onconetix, Inc. (ONCO)
0.7113
-0.05
(-5.96%)
USD |
NASDAQ |
Sep 14, 10:22
Onconetix Enterprise Value : -2.884M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | -2.884M |
| September 10, 2026 | -2.786M |
| September 09, 2026 | -2.668M |
| September 08, 2026 | -2.567M |
| September 04, 2026 | -1.884M |
| September 03, 2026 | -2.950M |
| September 02, 2026 | -3.195M |
| September 01, 2026 | -3.277M |
| August 31, 2026 | -3.376M |
| August 28, 2026 | -3.430M |
| August 27, 2026 | -3.356M |
| August 26, 2026 | -3.322M |
| August 25, 2026 | -3.314M |
| August 24, 2026 | -3.265M |
| August 21, 2026 | -3.286M |
| August 20, 2026 | -3.223M |
| August 19, 2026 | -3.056M |
| August 18, 2026 | -2.907M |
| August 17, 2026 | -2.880M |
| August 14, 2026 | -2.676M |
| August 13, 2026 | -2.406M |
| August 12, 2026 | -2.371M |
| August 11, 2026 | -2.080M |
| August 10, 2026 | -2.349M |
| August 07, 2026 | -2.371M |
| Date | Value |
|---|---|
| August 06, 2026 | -2.325M |
| August 05, 2026 | -1.941M |
| August 04, 2026 | -2.587M |
| August 03, 2026 | -2.676M |
| July 31, 2026 | -2.617M |
| July 30, 2026 | -2.77M |
| July 29, 2026 | -2.911M |
| July 28, 2026 | -2.604M |
| July 27, 2026 | -2.666M |
| July 24, 2026 | -2.638M |
| July 23, 2026 | -2.758M |
| July 22, 2026 | -2.415M |
| July 21, 2026 | -2.378M |
| July 20, 2026 | -1.960M |
| July 17, 2026 | -2.869M |
| July 16, 2026 | -2.750M |
| July 15, 2026 | -2.818M |
| July 14, 2026 | -2.534M |
| July 13, 2026 | -2.483M |
| July 10, 2026 | -2.189M |
| July 09, 2026 | -2.017M |
| July 08, 2026 | -2.120M |
| July 07, 2026 | -1.694M |
| July 06, 2026 | -1.580M |
| July 02, 2026 | -2.128M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| BridgeBio Pharma, Inc. | 16.84B |
| Aprea Therapeutics, Inc. | -30.92M |
| ACADIA Pharmaceuticals, Inc. | 3.908B |
| Alnylam Pharmaceuticals, Inc. | 32.94B |
| Anika Therapeutics, Inc. | 266.01M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.867M |
| Revenue (Quarterly) | 0.0171M |
| Total Expenses (Quarterly) | 2.884M |
| EPS Diluted (Quarterly) | -1.278 |
| Gross Profit Margin (Quarterly) | 25.15% |
| Profit Margin (Quarterly) | -16.77K% |
| Earnings Yield | -27.99K% |
| Normalized Earnings Yield | -35825.66 |